人血清中胞质氨基肽酶的评估。肝脏疾病中的评估。

Evaluation of cytosolic aminopeptidase in human sera. Evaluation in hepatic disorders.

作者信息

Kanno T, Maekawa M, Kanda S, Kohno H, Sudo K

出版信息

Am J Clin Pathol. 1984 Dec;82(6):700-5. doi: 10.1093/ajcp/82.6.700.

DOI:10.1093/ajcp/82.6.700

Abstract

Employing the quantitative electrophoretic separation of cytosolic "LAP" activity (EC. 3.4.11.1), the authors investigated the clinical significances of cytosolic and total "LAP" activities in the sera of patients with several different hepatic disorders and elucidated the previously confusing results of aminopeptidase measurements in clinical laboratories. The dominant aminopeptidases measured in human sera by L-leucinamide as substrate are both cytosolic "LAP" and microsomal aminopeptidase (EC. 3.4.11.2). Total "LAP" activity means the sum of these two aminopeptidases. Different substrate specificities are observed in these two enzymes located in other subcellular fractions and different increasing rates of these enzymes are observed in various hepatic diseases. In cases of acute hepatic cell damage, cytosolic "LAP" accounts for a large percentage of total "LAP" of a patient's serum. On the other hand, in cases of elevation of hepatobiliary enzymes, microsomal aminopeptidase constitutes a large part of total "LAP" activity, and the ratio between cytosolic and total "LAP" activity is very low.

摘要

作者采用定量电泳法分离胞质“亮氨酸氨基肽酶（LAP）”活性（EC. 3.4.11.1），研究了几种不同肝脏疾病患者血清中胞质和总“LAP”活性的临床意义，并阐明了临床实验室中氨基肽酶测量结果之前令人困惑的情况。以L-亮氨酰胺为底物在人血清中测量的主要氨基肽酶是胞质“LAP”和微粒体氨基肽酶（EC. 3.4.11.2）。总“LAP”活性指的是这两种氨基肽酶的总和。在位于其他亚细胞组分中的这两种酶中观察到不同的底物特异性，并且在各种肝脏疾病中观察到这些酶的不同增加速率。在急性肝细胞损伤的情况下，胞质“LAP”在患者血清总“LAP”中占很大比例。另一方面，在肝胆酶升高的情况下，微粒体氨基肽酶在总“LAP”活性中占很大一部分，并且胞质和总“LAP”活性之间的比率非常低。